Page last updated: 2024-10-15

acetylcarnitine and Prostatic Neoplasms, Castration-Resistant

acetylcarnitine has been researched along with Prostatic Neoplasms, Castration-Resistant in 1 studies

Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.

Prostatic Neoplasms, Castration-Resistant: Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.

Research Excerpts

Excerpt	Relevance	Reference
"Peripheral neuropathy (PN) is a recognized side effect of microtubule-targeting agents and the most clinically relevant toxicity observed with the epothilone sagopilone (SAG)."	2.78	A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. ( Baurain, JF; Berton-Rigaud, D; Campone, M; de Bont, N; Fabbro, M; Joly-Lobbedez, F; Pautier, P; Pinkert, J; Rolland, F; Schmelter, T; Stenzl, A; van Dijk, M, 2013)
"Methods."	2.78	A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. ( Baurain, JF; Berton-Rigaud, D; Campone, M; de Bont, N; Fabbro, M; Joly-Lobbedez, F; Pautier, P; Pinkert, J; Rolland, F; Schmelter, T; Stenzl, A; van Dijk, M, 2013)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Campone, M	1
Berton-Rigaud, D	1
Joly-Lobbedez, F	1
Baurain, JF	1
Rolland, F	1
Stenzl, A	1
Fabbro, M	1
van Dijk, M	1
Pinkert, J	1
Schmelter, T	1
de Bont, N	1
Pautier, P	1

Clinical Trials (3)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy： A Randomized, Controlled, Open-label, Phase 2 Trail[NCT05601479]	Phase 2	100 participants (Anticipated)	Interventional	2022-11-01	Not yet recruiting
Multi-Center, Randomized, Double-Blind Active-Controlled, Parallel Group Study to Investigate Plasma Folate, Red Blood Cell Folate and Homocysteine Levels During a 24 Week Oral Administration of an OC Containing Folate Compared to OC Alone[NCT00468481]	Phase 3	385 participants (Actual)	Interventional	2007-04-30	Completed
(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy.[NCT00751205]	Phase 2	150 participants (Actual)	Interventional	2008-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mean Change From Baseline in Plasma Folate Levels at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 12

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	17.6
Drospirenone (DRSP)/Ethinylestradiol (EE)	0.3

Mean Change From Baseline in Plasma Folate Levels at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 16

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	17.6
Drospirenone (DRSP)/Ethinylestradiol (EE)	2.4

Mean Change From Baseline in Plasma Folate Levels at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 20

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	15.1
Drospirenone (DRSP)/Ethinylestradiol (EE)	-1.6

Mean Change From Baseline in Plasma Folate Levels at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 4

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	15.2
Drospirenone (DRSP)/Ethinylestradiol (EE)	0.6

Mean Change From Baseline in Plasma Folate Levels at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 8

Intervention	µg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	18.4
Drospirenone (DRSP)/Ethinylestradiol (EE)	2.2

Mean Change From Baseline in Plasma Homocysteine Levels at Week 12

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 12

Intervention	µg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	-0.3
Drospirenone (DRSP)/Ethinylestradiol (EE)	0

Mean Change From Baseline in Plasma Homocysteine Levels at Week 16

Intervention	µg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)	-0.1

Mean Change From Baseline in Plasma Homocysteine Levels at Week 20

Intervention	µg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)	-0.2

Mean Change From Baseline in Plasma Homocysteine Levels at Week 24

Intervention	µg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	-0.3
Drospirenone (DRSP)/Ethinylestradiol (EE)	0.1

Mean Change From Baseline in Plasma Homocysteine Levels at Week 4

Intervention	µg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	0
Drospirenone (DRSP)/Ethinylestradiol (EE)	0

Mean Change From Baseline in Plasma Homocysteine Levels at Week 8

Intervention	µg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)	0

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 12

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	405.8
Drospirenone (DRSP)/Ethinylestradiol (EE)	86.5

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 16

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	448.9
Drospirenone (DRSP)/Ethinylestradiol (EE)	68.0

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 20

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	452.7
Drospirenone (DRSP)/Ethinylestradiol (EE)	64.6

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 4

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	110.9
Drospirenone (DRSP)/Ethinylestradiol (EE)	-37.6

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 8

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	310.3
Drospirenone (DRSP)/Ethinylestradiol (EE)	68.2

Mean Neural Tube Defect (NTD) Risk Reduction at Week 24

The mean NTD risk reduction evaluated as the change from Baseline to Week 24 in NTD risk based on the formula of Daly et al (J Amer Med Assoc 1995;274(21):1698-702); NTD risk=exp (1.6463-1.2193 x natural log [RBC folate]) where natural log [RBC folate] is the natural log of RBC folate measured in nmol/L; Change from Baseline to Week 24 in NTD risk=NTD risk at Week 24 - NTD risk at Baseline (NCT00468481)
Timeframe: Baseline and week 24

Intervention	per 1000 birth (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	-0.51
Drospirenone (DRSP)/Ethinylestradiol (EE)	-0.03

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	50.3
Drospirenone (DRSP)/Ethinylestradiol (EE)	47.1

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	67.4
Drospirenone (DRSP)/Ethinylestradiol (EE)	46.4

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	67.5
Drospirenone (DRSP)/Ethinylestradiol (EE)	51.8

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	61.5
Drospirenone (DRSP)/Ethinylestradiol (EE)	45.9

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	64.0
Drospirenone (DRSP)/Ethinylestradiol (EE)	43.7

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	60.4
Drospirenone (DRSP)/Ethinylestradiol (EE)	45.9

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	68.1
Drospirenone (DRSP)/Ethinylestradiol (EE)	54.1

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	41.7
Drospirenone (DRSP)/Ethinylestradiol (EE)	41.5

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	59.5
Drospirenone (DRSP)/Ethinylestradiol (EE)	42.3

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	59.4
Drospirenone (DRSP)/Ethinylestradiol (EE)	43.2

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	59.8
Drospirenone (DRSP)/Ethinylestradiol (EE)	39.7

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	58.7
Drospirenone (DRSP)/Ethinylestradiol (EE)	39.8

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	59.6
Drospirenone (DRSP)/Ethinylestradiol (EE)	43.1

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	60.8
Drospirenone (DRSP)/Ethinylestradiol (EE)	41.8

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1122.8
Drospirenone (DRSP)/Ethinylestradiol (EE)	1345.0

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1469.8
Drospirenone (DRSP)/Ethinylestradiol (EE)	1378.4

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1460.5
Drospirenone (DRSP)/Ethinylestradiol (EE)	1454.7

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1486.6
Drospirenone (DRSP)/Ethinylestradiol (EE)	1435.9

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1500.3
Drospirenone (DRSP)/Ethinylestradiol (EE)	1316.1

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1175.7
Drospirenone (DRSP)/Ethinylestradiol (EE)	1256.1

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1412.7
Drospirenone (DRSP)/Ethinylestradiol (EE)	1407.6

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	910.9
Drospirenone (DRSP)/Ethinylestradiol (EE)	915.1

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1308.9
Drospirenone (DRSP)/Ethinylestradiol (EE)	1025.2

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1365.2
Drospirenone (DRSP)/Ethinylestradiol (EE)	967.6

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1419.8
Drospirenone (DRSP)/Ethinylestradiol (EE)	981.3

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1355.3
Drospirenone (DRSP)/Ethinylestradiol (EE)	949.2

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1007.1
Drospirenone (DRSP)/Ethinylestradiol (EE)	889.5

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8

Intervention	nmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1184.8
Drospirenone (DRSP)/Ethinylestradiol (EE)	970.4

Plasma Folate Level at 24 Weeks

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: Week 24

Intervention	nmol/L (Least Squares Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	60.55
Drospirenone (DRSP)/Ethinylestradiol (EE)	41.67

Red Blood Cell (RBC) Folate Level at 24 Weeks

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: Week 24

Intervention	nmol/L (Least Squares Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)	1406.91
Drospirenone (DRSP)/Ethinylestradiol (EE)	1022.21

Trials

1 trial available for acetylcarnitine and Prostatic Neoplasms, Castration-Resistant

Article	Year
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. The oncologist, 2013, Volume: 18, Issue:11 Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind	2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. The oncologist, 2013, Volume: 18, Issue:11 Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind	2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. The oncologist, 2013, Volume: 18, Issue:11 Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind	2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. The oncologist, 2013, Volume: 18, Issue:11 Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind	2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. The oncologist, 2013, Volume: 18, Issue:11 Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind	2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. The oncologist, 2013, Volume: 18, Issue:11 Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind	2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. The oncologist, 2013, Volume: 18, Issue:11 Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind	2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. The oncologist, 2013, Volume: 18, Issue:11 Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind	2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. The oncologist, 2013, Volume: 18, Issue:11 Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind	2013